Search

everythinglearnresearchcommunity

for

Search:↓

User shared 3.5 months progress on oral finasteride 1.25mg daily with no side effects. Other users commented on the effectiveness and shared their experiences.

The conversation discusses managing estradiol problems during finasteride treatment. Suggestions include stopping finasteride every 3 months for 2-3 weeks or reducing the dosage.

The user experienced some hair regrowth after 4 months of inconsistent use of topical finasteride and minoxidil, with no noticeable side effects. Others suggest trying oral finasteride and minoxidil for better consistency.

The conversation discusses whether hair gained from using Pyrilutamide or RU58841 can be maintained with dutasteride if the former treatments are discontinued. The user prefers oral minoxidil for its effectiveness and convenience over topical applications.

The user experienced stable hairline but diffuse thinning after switching from oral finasteride to a topical solution of minoxidil and finasteride. They are concerned about the effectiveness of the topical treatment and are considering other options due to a recent decline in hair density.

A 27-year-old male experienced significant hair regrowth using 0.5 mg Dutasteride and 2.5 mg Oral Minoxidil daily, with minimal side effects. He noticed improvement in hairline and crown after an initial shedding phase, and he did not use Finasteride prior to this treatment.

OP switched from Finasteride to Dutasteride and experienced continuous hair shedding after 7 months but noticed no reduction in hair density. Other users advised patience, noting similar experiences and eventual hair improvement.

The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

The user shared their two-year progress using finasteride, noting hair stabilization without side effects and no use of minoxidil. They plan a hair transplant and emphasize finasteride's role in maintaining hair rather than regrowing it.

The user experienced hair loss and itching after stopping RU58841 and resumed it to stop these symptoms. They also use Dutasteride and question which treatment is effective.

The user is seeking advice on sourcing finasteride, dutasteride, and minoxidil, as their doctors are unwilling to prescribe both finasteride/dutasteride and minoxidil simultaneously. They are also looking for sources of GHK-Cu and RU58841 in the USA, with suggestions including using services like Hims, ro.co, and Musely.

The user experienced side effects from oral finasteride and tried mixing it with liquid minoxidil but faced application issues. They are seeking a 5% minoxidil foam with a maximum of 0.15% topical finasteride concentration.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The conversation discusses creating a 0.01% topical dutasteride solution mixed with minoxidil for hair loss treatment, with concerns about absorption and effectiveness. Some users suggest that dutasteride needs specific formulation for better absorption, while others recommend oral use for practicality.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

A user reports persistent sexual side effects three months after stopping finasteride, despite a healthy lifestyle and supplements. They express concern over the lack of libido and infrequent erections.

The user has been using homemade topical finasteride for over 2 years with no side effects and Rogaine foam, considering a hair transplant in a year. They are contemplating whether to continue the current treatment, switch to oral finasteride with or without RU58841, and are unsure about potential side effects of oral medication.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

The user experienced hair regrowth after 4 months of using 2.5 mg finasteride every other day and topical minoxidil 3-4 times a week, with occasional dermarolling. They feel their hair has returned to 2023 levels, and the scalp heat that led to thinning is gone.

OP experienced significant hair growth after switching from topical treatments to oral Dutasteride, alongside using CJC/Ipamorelin and Cialis. They stopped using topical Minoxidil and Finasteride, attributing the hair growth to the new regimen.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.

The user is experiencing side effects from Dutasteride 0.5 mg and is considering reducing its frequency or switching back to Finasteride, while continuing with Minoxidil 2.5 mg to preserve their hairline. They are unsure if the increased Minoxidil dose is sufficient for regrowth.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

The conversation discusses confusion over the dosage calculation of a topical solution containing 0.25% finasteride, 5% minoxidil, and 0.001% tretinoin. The user considers switching to a 0.025% finasteride solution to enhance the effects of tretinoin and minoxidil.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

The conversation is about finding the optimal concentration of topical melatonin for hair loss treatment. The user is considering making their own solution and is unsure whether a higher concentration is more effective for deactivating prolactin receptors.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.